Claims

1. Use of a composition for manufacture of a medicament for the treatment of a brain tumor, wherein the composition comprises a plurality of intact, bacterially derived minicells and wherein:

(a) each minicell comprises an antibody that specifically recognizes a tumor cell antigen, and

(b) the brain tumor has blood vessels with fenestrations in the vessel walls through which the minicells can extravasate passively.

2. The use of claim 1, wherein the plurality includes at least 10^8 minicells.

3. The use of claim 2, wherein the plurality includes at least 10^{10} minicells.

4. The use of any one of claims 1-3, wherein the composition comprises less than 10 endotoxin units (EU) free endotoxin.

5. The use of any one of claims 1-4, wherein the composition comprises at most 1 parent bacterial cell per 10^8 minicells.

6. The use of any one of claims 1-5, wherein each minicell of the plurality comprises a ligand having a specificity to a non-phagocytic mammalian cell surface receptor.

7. The use of claim 6, wherein the receptor is a tumor cell antigen.

8. The use of any one of claims 1-7, wherein the brain tumor is selected from the group consisting of glioblastoma, astrocytic tumor, oligodendroglial tumor, ependymoma, craniopharyngioma, pituitary tumor, primary lymphoma of the brain, pineal gland tumor, primary germ cell tumor of the brain, and combinations thereof.

9. The use of claim 8, wherein the brain tumor is a metastatic brain tumor.

10. The use of claim 1, wherein the brain tumor is glioblastoma.

11. The use of claim 1 or 10, wherein the tumor is a stage II, III, or IV tumor.

12. The use of claim 1 or 10, wherein the tumor is a stage III or IV tumor.

13. The use of claim 1 or 10, wherein angiogenesis has initiated in the tumor.

14. The use of claim 1 or 10, wherein vascularization has initiated in the tumor.

15. The use of claim 1, wherein the minicells are derived from *S. typhimurium* or *E. coli* bacteria.

16. The use of claim 1, wherein the antibody is a bi-specific antibody.

17. The use of claim 1, wherein the tumor cell antigen is EGFR or HER-2.